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Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in main-
tenance hemodialysis patients with/without diabetes mellitus. We studied
the quantitative and qualitative characteristics of lipoprotein(a) [Lp(a)]
as a function of apolipoprotein(a) [apo(a)1 phenotypes in 152 patients
(123 males, 29 females) undergoing maintenance hemodialysis (HD)
with or without diabetes mellitus (DM), in 101 patients with diabetes
mellitus without hemodialysis (58 males, 43 females), and in 421 normal
controls (333 males, 88 females). Serum Lp(a) levels were significantly(P < 0.01) higher in patients than in controls (26.2 18.3 mg/dl in HD
with DM, 26.4 22.0 mg/dl in HD without DM, 27.1 27.3 mg/dl in
DM without HD, and 14.9 13.7 mg/dl in controls, respectively).
Apo(a) phenotyping was performed by a sensitive, high resolution
technique using SDS-agarose/gradient (3 to 6%) PAGE. In normal
controls, the molecular weights of apo(a) isoforms were inversely
correlated with plasma Lp(a) levels, and the same tendency was found
in patients who were undergoing hemodialysis and/or who had diabetes
mellitus. We assumed the differences in apo(a) phenotypes detectable
with our method reflected consecutive differences in molecular weights
of apo(a). The results of an analysis of covariance and a least square
means comparison indicated that the regression lines between serum
Lp(a) levels [log Lp(a)] and apo(a) phenotypes in patient groups were
significantly (P < 0.01) elevated for every apo(a) phenotype, as com-
pared to the regression line of the control group. Even after the low
molecular weight apo(a) phenotypes (Al-A8) were omitted, the same
tendency was observed. However, no differences were observed be-
tween the patient groups. The frequency distributions of serum Lp(a)
levels in the patient groups were significantly different at every cut off
point [10, 20, 30, 40, and 50 mg/dl of Lp(a)1 from those in the control
group, as assessed by chi square statistics. These data indicate that
serum Lp(a) levels are controlled by alleles at the apo(a) locus in
patients undergoing hemodialysis, as well as in patients with diabetes
mellitus, but that increased Lp(a) levels in hemodialysis and diabetic
patients are not regulated by genes encoding low molecular weight of
apo(a) isoforms.
Lipoprotein(a) [Lp(a)] is a cholesterol-rich lipoprotein which
has a composition similar to that of low density lipoprotein
(LDL). Apolipoprotein(a) [apo(a)], an important constituent of
Lp(a), is a glycoprotein which shows a high homology to
plasminogen, and is linked to apo B-l00 by disulfide bridges in
Lp(a) [1—5]. Many clinical reports have shown that elevated
levels of Lp(a) are associated with an increased risk for coro-
nary ieart disease (CHD) [6—9], and Lp(a) is assumed to be an
indepcndent risk factor for CHD. Recent studies have shown
that higher concentrations of plasma Lp(a) can also be seen in
patients with diabetes mellitus (DM) [10, 11], or who are
undergoing hemodialysis (HD) or continuous pentoneal dialysis
[12—15]. We previously reported that serum Lp(a) levels in
hemodialysis patients were significantly higher, and that the
frequency distributions of serum Lp(a) levels in these patients
differed from those in a normal control group [16].
Plasma Lp(a) levels in humans vary from less than 1 mgldl to
more than 100 mg/dl, and these levels are genetically controlled
by apo(a) polymorphism, that is, individuals who carry iso-
forms with lower molecular weights are more likely to have
higher levels of plasma Lp(a) than individuals who carry
isoforms with larger molecular weights [17—19]. Since Uter-
mann et al first reported a genetic size polymorphism of six
apo(a) isoforms with different molecular weights [17], several
other researchers have detected additional apo(a) isoforms [20,
21]. We have recently detected 26 different apo(a) alleles,
including a null allele, at the apo(a) locus by a sensitive, high
resolution technique using SDS-agarose/gradient PAGE, and
have observed a highly significant inverse correlation between
serum Lp(a) levels and the size of apo(a) isoforms [22].
Lipid abnormalities have also been observed in patients with
renal disease, such as nephrotic syndrome and end-stage renal
disease, and in patients with diabetes mellitus [23—27]. There-
fore, we determined apo(a) phenotypes, serum Lp(a) levels,
and other lipid and lipoprotein levels, in patients who were
undergoing maintenance hemodialysis with/without diabetes
mellitus, as well as in patients with diabetes mellitus without
hemodialysis. This paper reports the results of our investigation
of the quantitative and qualitative characteristics of Lp(a) and
its relationship to the diseased state as a function of apo(a)
phenotypes.
Methods
Patients
One hundred and fifty-two patients (123 males, 29 females,
from 23 to 77 years old, 56.1 11.6 years) undergoing mainte-
nance hemodialysis (17 of whom had coronary heart disease),
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101 patients with non-insulin dependent diabetes mellitus
(NIDDM) (58 males, 43 females, from 42 to 89 years old, 63.9
10.8 years) and 421 normal controls (333 males, 88 females,
from 19 to 69 years old) recruited from eight different hospitals,
were studied. Controls were selected from individuals who had
received an annual medical check-up at three different hospi-
tals. Among the hemodialysis patients, 30 (21 males, 9 females)
were receiving maintenance hemodialysis because of diabetic
nephropathy, 18 (18 males) other diabetes patients were on
maintenance hemodialysis but the etiology of renal failure were
unknown, and 122 patients (101 males, 21 females) were receiv-
ing hemodialysis for other reasons, such as nephrosclerosis (N
= 11), chronic glomerulonephntis (N = 48), renal cell carci-
noma (N = 1), polycystic kidney (N = 2), pyelonephritis (N =
3), IgA nephropathy (N = 4), gout (N = I), systemic lupus
erythematosus (N = 2), rheumatoid arthritis (N = 1), rapidly
progressive glomerulonephntis (N = 1), and unknown etiology(N = 48). Although a renal biopsy was not conducted in all
patients, the reasons for hemodialysis depended, in part, on a
clinical diagnosis. The duration of hemodialysis ranged from 1
to 252 months (66.9 51.3 months). None of the patients were
treated with CAPD. The dialysis schedule was four or five
hours three times a week. We used a 0.8 to 2.1 m2 surface area
hollow-fiber filter [cuprophan membrane (31.7% of the pa-
tients), triacetate membrane (13.1%), modified cellulose mem-
brane (14.5%), saponificated cellulose membrane (1.4%), poly-
methylmethacrylate membrane (PMMA; 23.5%), ethylenevinyl
alcohol copolymer membrane (EVA; 5.5%), polysulfon mem-
brane (10.3%)], and bicarbonate dialysate containing sodium
140 mEq/liter, kalium 2.0 mEq/liter, calcium 3.0 mEq/liter,
chlorine 110 mEq/liter, acetate 8.0 mEq/liter, carbonic acid 30
mEq/liter, and glucose 100 mg/dl or 150 mg/dl (150 mg/dl was
used for insulin-treated diabetic patients).
Among the diabetic patients without hemodialysis, 10 pa-
tients were receiving insulin treatment, 55 were receiving oral
hypoglycemic agents, and 36 patients were receiving single diet
therapy. Diagnosis of diabetes was based on intolerance to 75
grams of oral glucose, the use of oral hypoglyceridemic agents,
or insulin therapy. Diagnosis of hypertension was based on
blood pressure above 160/95 mm Hg more than two times, or
the use of anti-hypertensive drugs. Diagnosis of coronary heart
disease was based on coronary angiography, electrocardio-
gram, or clinical heart attack episodes. While some of the
patients were treated with anti-hypertensive drugs, neither
diuretics nor beta-blockers were used. Therefore, there was
minimal possibility of adverse effects from antihypertensive
drugs on lipid metabolism, including that of Lp(a). Hypolipid-
emic agents were not used in the patient and control groups.
Chemical determinations
Blood sampl.s were taken before hemodialysis and after
overnight fasting. Serum total cholesterol (TC) and triglycerides
(TG) were determined by enzymatic methods [28, 29]. The
heparin CaCI2 precipitation method was used to assay serum
high-density lipoprotein cholesterol (HDL-C) [30]. Low-density
lipoprotein cholesterol (LDL-C) was calculated using the for-
mula of Friedewald, Levy and Fredrickson [31]. HDL2 and
HDL3 subfractions were separated by an ultracentrifugation
method [30, 32]. Serum apo Al, apo All, apo B, apo CII, apo
CIII, and apo E levels were determined by the turbidity
immunoassay (TIA) method [33]. Serum Lp(a) was determined
by ELISA using a Tint Eliza Lp(a) kit (Biopool, Sweden) [34].
Urine proteins (albumin) were measured using spot urine ad-
justed for urinary creatinine as described by Takegoshi et a!
[11]. Urinary albumin was assayed by an immunoturbidity
method using a Riket Albumin kit (Japan Chemipha, Tokyo)
[35]. Interassay and intra-assay coefficient variations of all
measurements in our laboratory were less than 5.5%.
Plasma lipoprotein isolation
Venous blood was collected in EDTA tubes and then centri-
fuged at 4°C. The plasma (approximately 1 ml) fraction at
density <1.12 g/ml was separated by ultracentrifugation for four
hours (using a Beckman TL-100 Tabletop Ultracentrifuge,
TLA-lOO.2 fixed anglerotor), using polycarbonate centrifuge
tubes. Tube slicing was performed using a Centrifuge Slicer
(Beckman Instruments, Inc., Palo Alto, California, USA).
Apo(a) phenotyping
Apo(a) phenotyping was performed in 101 hemodialysis pa-
tients without diabetes mellitus, 44 hemodialysis with diabetes
mellitus, 94 diabetes mellitus, and 215 control subjects. Apo(a)
phenotyping was performed by the method of Kikuchi et al [22].
Briefly, 2 to 5 d lipoprotein fraction (d < 1.12 g/ml) was mixed
with an equal volume of a sample buffer which contained 0.25 M
Tris-HCI (pH 6.8), 20% sucrose, 10% SDS, 10% 2-mercapto-
ethanol, and 0.02% BPB. For the stacking gel, 1.2% agarose gel
containing 0.125 M Tris-HC1 (pH 6.8), 0.2% SDS, and 0.5%
2-mercaptoethanol was used instead of polyacrylamide gel. For
the running gel, we used 3 to 6% gradient polyacrylamide slab
gels containing 0.375 M Tris-HC1 (pH 8.8) and 0.2% SDS. The
running buffer contained 25 msi Tris, 0.19 M glycine, and 0.2%
SDS. A control sample contained the lipoprotein fraction from
four individuals. Electrophoresis was performed at a constant
current of 5 mA for three hours and then at 3 mA for an
additional 18 hours at room temperature. Electrophoretic trans-
fer of protein from gel to nitrocellulose membrane filters (BA83,
Schleicher & Schull) was performed for two hours at a constant
current of 180 mA with a blotting buffer (7 x Running buffer
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Fig. 1. Serum Lp(a) concentrations in patients with hemodialysis
without diabetes mellitus (N = 104), hemodialysis with diabetes melli-
tus (N = 48), diabetes mellitus without hemodialysis (N = 101), and
controls (N = 421). * P < 0.01.
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Fig. 2. Frequency distribution of plasma
Lp(a) concentrations in patients with
hemodialysis without diabetes mellitus (fl, N
= 104), hemodialysis with diabetes mellitus(, N = 48), diabetes mellitus without
hemodialysis (, N = 101) and controls (•,
N = 421).
Table 1. Serum lipids, lipoproteins, and apolipoproteins in patients and controls
HD without
DM
HD with
DM
DM without
HD Controls
N 104 48 101 421
TC 168.1 357c 154.8 41.6c 215.8 554C 178.5 24.3
TG 130.6 72.lc 125.8 78,lc 192.0 272.2 84.1 30.2
HDL-C 39.3 13.lc 33.1 i1.7 47.2 l4.2c 52.7 13.3
LDL-C 102.7 31.Oa 96.4 29.8c 130.1 54.3 108.9 24.1
HDL2-C
HDL3-C
apoAl
24.0 lO.3c
16.1 3.7k'
107.4 20.6a
20.7 9,lc
13.8 3,3C
95.2 21.3c
28.8 1l.6c
19.6 44b
128.7 30.5"
35,2 10.4
20.6 3.2
135.2 21.3
apo All 25.5 59C 21.6 6,3c 32.5 10.0 29.0 4.3
apo B 85.0 24.3c 81.8 28.3" 105.6 34.1c 72.4 14.7
apo CII 3.6 l.7c 3.2 1.8c 4.8 3.lc 2.8 1.1
apo CIII 15.7 59C 12.7 1,8c 13.8 l0.8 8.5 2.3
apo E 5.0 1.8c 4,7 1.8 6.8 5,9C 4.1 1.0
ap< 0.1
b P < 0.05
P < 0.01
containing 10% methanol). The filter was blocked with 0.2%
gelatin in PBS and incubated in 1% BSA in PBS containing
0.1% anti-apo(a) monoclonal antibody. The anti-apo(a) mono-
clonal antibody was prepared using purified human apo(a) and
did not cross react with human plasminogen or other plasma
proteins (Nakagawa et al, unpublished observations). Peroxi-
dase-conjugated anti-mouse IgG rabbit serum (0.1% in PBS)
was used as the second antibody, and the patterns were
visualized using 0.01% DAB and 0.1% H202 in PBS.
Statistical procedures
All calculations were performed using the Statistical Analysis
System (SAS). The data are all presented as the mean SD.
Because a Kolmogorow-Smirnov test showed significant devi-
ation from the normal distribution for some biochemical vari-
ables, the Mann-Whitney U test was used to compare values in
the patient groups with those of the controls. P values of less
than 0.05 were considered to indicate statistical significance.
Chi square analysis was used to examine the frequency distri-
bution of Lp(a) levels in patients and controls. Analysis of
covariance was used to compare groups after adjusting for
confounding factors (age, sex, diseases) and apo(a) phenotypes,
and least square (LS) means were also compared alter log
transformation of Lp(a) and after adjusting for apo(a) pheno-
types to gain a better understanding of the relationship between
the frequency distribution of apo(a) phenotypes and serum
Lp(a) levels in diseased and control groups.
Results
Serum Lp(a) concentrations in patients with hemodialysis but
without diabetes mellitus (N 104), with hemodialysis and
diabetes mellitus (N = 48), with diabetes mellitus but without
hemodialysis (N = 101) and controls (N = 421) were 26.4 22.0
mgldl, 26.2 18.3 mgldl, 27.1 27.3 mg/dl, and 14.9 13.7
mgldl, respectively (Fig. 1). The Mann-Whitney U test showed
that Lp(a) and log Lp(a) levels were significantly (P < 0.01)
higher in patient groups than in controls, however, no signifi-
cant differences were observed between the three different
patient groups. The distributions of serum Lp(a) concentrations
in the above groups are shown in Figure 2. The median values
9 9 N) 9 0) 9 a 
r9
 
0) 
01
 
39
 9 -.4 9 9 CD 9 0 9 
a
 
0,
 
0 
0 
Hirata et a!: Apo!ipoprotein(a) phenotypes in hemodialysis 1065
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Fig. 3. Apo(a) phenolyping using 3 to 6% SDS-a garosel gradient PA GE followed by immunoblot analysis. Lane 1: A12A14, Lane 3: A15A19, Lane
4: A3A15, Lane 5: A14A19, Lane 7: A17A20, Lane 9: A18A25, Lane 10: A18A19, Lane 12: A6A21, Lane 13: A3A19, Lane 15: A12, Lane 16:
A15A18, Lane 18: A16A18, Lane 19: A9, Lane 21: A18, Lane 22: A8A16, Lane 24: A16A18, Lanes 2,6,8, 11, 14, 17, 20, and 23: a marker mixture
(M) containing apo(a) isoforms AlO, A12, A14, A16, A18 and A21.
and ranges of Lp(a) concentrations in hemodialysis without
DM, hemodialysis with DM, DM without hemodialysis, and
controls were 21.5 (0.5 to 113) mg/dl, 22.5 (0.5 to 98) mg/dl, 18.0
(ito 132) mgldl, and 10.9 (0.4 to 112) mgldl, respectively. In our
present study, diabetic or hemodialysis patients often had other
atherosclerotic factors, that is, hypertension, coronary heart
disease, hyperlipoproteinemias, etc. Therefore an analysis of
covariance was performed after making adjustments for age,
sex, presence of hypertension, coronary heart disease, diabetes
mellitus, hyperlipoproteinemias and hemodialysis. Hemodialy-
sis treatment was found to most significantly (P < 0.01)
contribute to the elevated serum Lp(a) levels, although the R2
value was low (R2 = 0.04).
Serum lipid and lipoprotein levels were also determined in the
four different groups (Table 1). Serum TC levels in hemodialysis
without DM and with DM were 168.1 35.7 mgldl and 154.8
41.6 mgldl, respectively, which were lower (P < 0.01) than that
in the control group (178.5 24.3 mgldl). Serum TC in DM
without hemodialysis was 215.8 55.4 mgldl, which was
significantly higher than that in controls. Serum HDL-C (39.3
13.1 mgldl, 33.1 11.7 mg/dl, 47.2 14.2 mg/dl, 52.7 13.3
mg/dl, respectively), HDL2-C (24.0 10.3 mgldl, 20.7 9.1
mgldl, 28.8 11.6 mgldl, 35.2 10.4 mgldl, respectively), and
HDL3-C (16.1 3.7 mg!dI, 13.8 3.3 mg/dl, 19.6 4.4 mg/dl,
20.6 3.2 mgldl, respectively) were significantly lower (P <
0.05) in the patientgroups. Serum TO (130.6 72.1 mgldl, 125.8
78.1 mgldl, 192.0 272.2 mg/dl, 84.1 302 mg/dl, respec-
tively), apo B (85.0 24.3 mgldl, 81.8 28.3 mg/dl, 105.6
34.1 mgldl, 72.4 14.7 mg/dl, respectively), apo CII (3.6 1.7
mg/dl, 3.2 1.8 mg/dl, 4.8 3.1 mg/dl, 2.8 1.1 mg/dl,
respectively), apo CIII (15.7 5.9 mgldl, 12.7 1.8 mg/dl, 13.8
10.8 mgldl, 8.5 2.3 mg/dl, respectively) and apo E (5.0
1.8 mg/dl, 4.7 1.8 mg/dl, 6.8 5.9 mg/dl, 4.1 1.0 mg/dl,
respectively) levels were significantly (P < 0.05) higher in the
patient groups.
In our investigation, 25 different types of apo(a) isoforms
were identified by immunoblot analysis following SDS-agarose/
gradient (3 to 6%) PAGE [22]. An example of apo(a) phenotyp-
ing is shown in Figure 3. A marker mixture (M) containing
apo(a) polymorphs AlO, A12, A14, Al6, A18, and A21 was
applied to each lane as shown in Figure 3, and the phenotyping
was performed as described above. Approximately 75% of the
subjects had a double band of apo(a), while the remaining
subjects had a single band. When the subject had a double band,
the smaller band was used for the expression of phenotypes in
the analysis of the relationship between serum Lp(a) levels and
apo(a) isoforms, because the smaller band was well correlated
with Lp(a) levels in double-banded phenotypes [22]. In normal
controls, apo(a) isoforms were a strong detennining factor of
serum Lp(a) levels (Fig. 4D), that is, an increase in the
molecular weight was significantly (P < 0.01) correlated with
decreased levels of serum Lp(a). In patients undergoing hemo-
dialysis with/without DM, or DM without hemodialysis, a
similar tendency (P < 0.01) was observed (Fig. 4A, B, C).
In order to assess the percentage changes in Lp(a) at any
isoform more accurately, serum Lp(a) levels were transformed
into logarithms, since log transformation should provide the
percent changes of Lp(a) at each isoform. The regression lines
based on log Lp(a) are presented in Figure 5. We used an
analysis of covariance, and least square (LS) means were
compared after adjusting for apo(a) phenotypes. The lines of the
diseased groups were significantly (P <0.01) higher than that of
the control group. In the group of hemodialysis with diabetes,
we used the data from A9 to A20 since there were fewer
patients in other phenotypes. Even when an analysis of co-
variance was performed between A7 to A25 or A9 to A25, after
omitting the low molecular weight isoproteins (Al-A6, or to
A8), the regression lines of the control and diseased groups
were significantly different. Furthermore, we tentatively
grouped these 25 different apo(a) phenotypes into three differ-
ent subgroups (A2-A9, AlO-A16, and A17-A25) and compared
their serum Lp(a) levels. Serum Lp(a) levels of these subgroups
in the control were 42.0 24.6 mg/dl, 17.7 9.6 mg/dl, 8.6
5.9 mgldl, respectively, which were all significantly (P <0.05)
less than those in the diseased groups (Table 2).
Duration of hemodialysis versus Lp(a) concentration is
shown in Figure 6A. We divided the patients into three groups
based on the duration of hemodialysis: <12 months, 12 to 60
months and >60 months. However, no significant differences
were observed between the three groups. Whether or not
diabetes was controlled (HbAlc > 7.0% or 7.0%; Figure 6B)
did not affect the correlation between serum Lp(a) levels and
apo(a) phenotypes. For the assessment of diabetic nephropa-
thy, we divided the patients into three groups with proteinuria,
<30 mglg creatinine, 30 to 300 mg/g creatinine, and >300 mglg
creatinine. After adjusting for apo(a) phenotypes, no significant
differences were observed between the three groups (Fig. 6C).
Lp(a) frequency distributions with cut off points at 10, 20, 30,
40, and 50 mg/dl of Lp(a) in hemodialysis patients with or
without DM and in diabetes mellitus were assessed by
statistics (Table 3). The frequency distributions of Lp(a) in the
M M M M M M
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Fig. 4. Correlation of serum Lp(a) concentrations and apo(a) polymor-
phism in patients with (A) hemodialysis without diabetes mellitus (N =
101), (B) hemodialysis with diabetes mellitus (N = 44), (C) diabetes
mellitus without hemodialysis (N = 94), and (D) controls (N = 215).
three patient groups were significantly different from that in the
control group at every cut off point used.
Discussion
Accelerated atherosclerosis and cardiovascular disease are
frequently observed in patients with end-stage renal disease or
diabetes mellitus [6, 10, 11, 14—16]. Elevated serum Lp(a) levels
have been associated with premature coronary heart disease
A A A A A A
1 5 10 15 20 25
Apo(a) isoform phenotype
Fig. 5. The regression lines of the correlation of serum Lp(a) concen-
trations and apo(a) polymorphism in patients with (A) hemodialysis
without diabetes mellitus (y = 2.2732 — 6.8018e — 2x, R2 = 0.375), (B)
hemodialysis with diabetes mellitus (y = 2.1 747 — 5.3797e — 2x, R2 =
0.270), (C) diabetes mellitus without hemodialysis (y = 2.2261 —
6.7825e — 2x, R2 = 0.371), and(D)controls(y = 1.9628 — 6.0655e — 2x,
R2 = 0.433).
apo(a) isoform
A1-A9 Al0-A16 A17-A25
Controls 42.0 24.6 17.7 9.6 8.6 5.9
N = 215
HD without DM
N = 16 (7.4%)
84.5 189b
N 99 (46.0%)
28.7 143b
N = 100(46.5%)
13.6
N = 101 N 8 (7.9%) N = 52 (51.5%) N = 41(40.6%)
HD with DM 31.3 203b 19.1 124b
N = 44
DM without HD
N = 0 (0.0%)
76.3 41.Ol
N = 23 (52.3%)
27.5 17.5"
N = 21(47.7%)
12.7 11.5k
N = 94 N = 12 (12.8%) N = 44 (46.8%) N = 38 (40.4%)
ap 0.05
b P < 0.01, compared with control
and other atherosclerotic diseases [6—9, 36], as well as with the
diseased states mentioned above [10—12, 16]. Atherogenic lipid
abnormalities are also likely to be present under such condi-
tions (Table 1). Thus, the combination of hyperlipoproteinemia
and elevated Lp(a) levels may play a role in the progression of
atherosclerosis. Our study demonstrated that serum Lp(a)
levels were elevated in patients undergoing hemodialysis with!
without diabetes and in simple diabetic patients.
There is little debate regarding whether elevated Lp(a) levels
are associated with atherosclerotic diseases, but it is unclear
whether serum Lp(a) levels are also increased in diabetic
patients [37—39]. Haffner et al have reported that Lp(a) levels
did not increase in NIDDM patients [39], while we observed
higher Lp(a) levels in patients with diabetes mellitus (Fig. 1).
This difference may be due to two factors: (1) the patients in the
present study were not selected from a well controlled popula-
tion, as in the study by Haffner et al, and (2) many of our
diabetic patients had other atherosclerotic conditions, such as
coronary heart disease (10.7%), hyperlipoproteinemias (52.4%),
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Apo(a) isoform phenotype (•) 30 to 300 mglg creatinine, and (0) >300
mg/g creatznlne.
hypertension (53.4%), etc. Thus, elevated LDL-C levels in
diabetic patients (Table 1) may have produced elevated Lp(a)
levels, as suggested by Schernthaner et al [10].
However, after adjusting for age, sex, and presence of
hypertension, coronary heart disease, diabetes mellitus, hyper-
lipoproteinemias, and hemodialysis, an analysis of covariance
showed that hemodialysis treatment, rather than diabetes, most
significantly (P < 0.01) contributed to the elevated serum Lp(a)
levels, although the R2 value was low (R2 = 0.04). In addition,
since the mean duration of hemodialysis in our study was
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HD - DM
HD + DM
DM
Controls
24 (22.9)
8 (16.3)
32 (30.8)
235 (56.9)
Total
N Lp(a) 20 (mg/dl)N(%)
>20
N(%)
HD — DM
HD + DM
DM
Controls
105
49
104
413
Total
N
51(48.6)
23 (46.9)
55 (52.9)
326 (78.9)
Lp(a) 30 (mgldl)
N(%)
54 (51.4)8
26 (53.1)8
49 (47.1)8
87 (21.1)
>30
N(%)
LID — DM
HD + DM
DM
Controls
105
49
104
413
Total
N
72 (68.6)
34 (69.4)
71(68.3)
378 (91.5)
Lp(a) 40 (mgldl)
N(%)
33 (31.4)a
15 (30.6)8
33(31.7)8
35 (8.5)
>40
N(%)
HD — DM
HD + DM
DM
Controls
105
49
104
413
Total
N
90 (85.7)
39 (80.0)
82 (78.9)
398 (96.4)
Lp(a) 50 (mgldl)
N(%)
15 (14.3)a
10 (20.0)a
22 (21,1)8
15 (3.6)
>50
N(%)
HD — DM
LID + DM
DM
Controls
105
49
104
413
94 (89.5)
44 (89.8)
91(87.5)
404 (97.8)
11 (10.5)a
5 (10.2)a
13 (12,5)8
9 (2.2)
approximately five years the patient population may have been
skewed; the presence of diabetes mellitus and coronary heart
disease at the initiation of hemodialysis may affect the mortality
of such patients. However, Takegoshi et al [11] showed that
Lp(a) levels are significantly higher in patients with diabetes
mellitus and chronic renal failure than in patients without
chronic renal failure. A recent study by Kandoussi et al [15]
measured plasma Lp(a) levels in predialysis and hemodialysis
patients, and in patients on CAPD. They found that the Lp(a)
levels in the former two groups were similar and greater,
respectively, than those in controls and CAPD-treated patients.
In addition, no difference was observed between controls and
CAPD patients. These findings suggest that CAPD treatment
rather than hemodialysis may affect apo(a) metabolism. On the
other hand, Haffner et al [14] reported that the type of therapy
used to treat renal failure does not influence Lp(a) levels.
Neither study adjusted for apo(a) phenotyping. In our protocol
it was difficult to determine the predialysis serum Lp(a) levels of
so many patients since they were already undergoing hemodi-
alysis. Therefore, chronic renal failure during its early phase
may hold the key to increase serum Lp(a) levels.
Low albuminemia in nephrotic syndrome triggers increased
hepatic production of proteins, including lipoproteins [16, 23—
26]. However, neither the hemodialysis patients nor the pa-
tients with diabetes mellitus in the present study showed low
serum albuminemia. Serum Lp(a) levels in patients with diabe-
tes with or without nephropathy (Fig. 6C) also showed no
significant differences. Apparently, renal disorder is not in-
volved in increasing Lp(a) levels in diabetic patients, and
further, the presence of diabetes does not affect serum Lp(a)
levels in patients undergoing hemodialysis (Fig. 5).
It has been shown that the apo(a) gene could account for
more than 90% of the differences between serum Lp(a) concen-
trations in different individuals within a pedigree [19]. An
inverse correlation between the size of apo(a) isoforms and the
concentrations of Lp(a) has been reported in population and
family studies [17—19, 22]. We used an analysis of covariance,
assuming that differences in the apo(a) phenotypes (Al to A25)
reflect consecutive differences in molecular weights of apo(a),
and found that (Fig. 5) the regression lines of patient and control
groups were almost parallel, that is, the regression line in
diabetic patients and hemodialysis patients with/without diabe-
tes mellitus presented elevated Lp(a) [log Lp(a)] levels, and
serum Lp(a) [log Lp(a)] levels in such patients were signifi-
cantly (P < 0.01) higher than those in controls for every apo(a)
phenotype, after adjusting for confounding apo(a) isoforms. A
similar analysis was performed in the three different patient
groups, but no statistically significant difference was observed.
The distribution of apo(a) isoforms and serum Lp(a) levels in
hemodialysis patients with diabetes seemed to differ from those
in other diseased groups, perhaps because of the rather small
number of patients studied, although tendencies similar to those
in the control group were also observed, Even after omitting the
low molecular weight apo(a) phenotypes (Al to A8), the same
tendency was observed in other two diseased groups. Since we
previously reported that the average molecular difference be-
tween adjacent apo(a) isoforms was estimated to be 18.4 kDa
from A5 to A24 [22], the molecular weight differences from Al
to A4 were rather larger, which may have slightly biased the
regression lines. However, this should not have affected the
percent changes of Lp(a) between the control and diseased
groups, because Lp(a) was transformed into a logarithm. The
apo(a) isoforms were again arbitrarily divided into three differ-
ent groups (Al-A9, Al0-A16 and A17-A25), and the Lp(a) levels
in these three groups were significantly (P < 0.01) higher in
patient groups than in controls (Table 2), The differences
observed between the regression lines of the control and
diseased groups in Figure 5 essentially matched the Lp(a)
frequency distribution shown in Figure 4 and Tables 2 and 3. All
of these results indicate that the increases in serum Lp(a) levels
in patients undergoing hemodialysis and in diabetic patients
were not linked to any particular low molecular weight apo(a)
isoform, and it may support the idea that there is no difference
in the genetic expression of apo(a) in hemodialysis and diabetic
patients as compared to normal populations. These findings
differ from those observed in patients with intermittent claudi-
cation, where the elevated Lp(a) levels were due to a prepon-
derance of low-molecular weight apo(a) isoforms [36].
Lp(a) in vivo kinetic studies have led to a better understand-
ing of the mechanism of low and high serum Lp(a) levels,
although to date such studies have only been performed in
Table 3. Frequency distributions of serum Lp(a) levels of five
different cut off points in patients and control
Lp(a) lO (mg/dl)
N (%)
Total
N
105
49
104
413
>10
N (%)
81 (77.1)a
41(83,7)8
72 (69.2)8
178 (43.1)
a p < 0.05 (vs. controls), (HD-DM:HD without DM, HD + DM:HD
with DM, DM:DM without HD
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familial hypercholesterolemia, sporadic hyperlipoproteinemia
and normolipidemic subjects [40, 41]. Each condition studied
showed similar fractional catabolic rates for apo(a). This sug-
gests that synthesis, rather than the catabolic pathway, may
play a key role in setting serum Lp(a) levels. On the other hand,
a recent study by Portman et al [42] demonstrated an acquired
defect in LDL receptor function in lymphocytes from uremic
patients. Therefore, if Lp(a) can be specifically cleared by LDL
receptors [40, 43], then increased Lp(a) levels in hemodialysis
patients may result from the diminished Lp(a) catabolic path-
way. However, this would only explain the increased Lp(a)
levels in hemodialysis patients, and not those in diabetic
patients. In the present study we demonstrated that there was
no difference between the serum Lp(a) levels of diabetic pa-
tients with or without nephropathy (proteinuria), although
microalbuminuria itself could be an independent risk factor for
cardiovascular disease [44]. Although present, urinary loss of
Lp(a) did not affect catabolic rates of Lp(a). Furthermore,
neither the control of diabetes as assessed by HbAlc [37] nor
proteinuria affected serum Lp(a) levels (Fig. 6, B and C). These
results strongly suggest that Lp(a) synthesis may be increased
with hemodialysis and diabetes mellitus, regardless of the
apo(a) phenotypes. It would be interesting to determine the
kinetic parameters of Lp(a) from various apo(a) alleles in
patients undergoing hemodialysis or with diabetes mellitus. An
in vivo kinetic study of this type could not be performed in the
present case for ethical reasons.
When the frequency distribution pattern was assessed by a
chi square test with cut off points at 10, 20, 30, 40, and 50 mgldl
of Lp(a) (Table 3), significant distribution differences were
observed in patient groups at every level of Lp(a) as compared
to the control group, but no significant distribution differences
were observed between the patient groups. These results also
suggest an increased synthesis of apo(a) despite the distribution
of apo(a) phenotypes. Chronic renal failure and diabetes melli-
tus may be linked to the increased levels of Lp(a). Furthermore,
they may be secondary factors that increase serum Lp(a) levels.
However, the mechanism which produces an elevated Lp(a)
level and the mechanism which produces high and low Lp(a)
levels within the same apo(a) phenotype among different mdi-
viduals are still unknown.
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